Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
-
Nate Bargatze to host Emmys: organizers
-
US Fed Chair warns of 'tension' between employment, inflation goals
-
Trump touts trade talks, China calls out tariff 'blackmail'
-
US judge says 'probable cause' to hold govt in contempt over deportations
-
US eliminates unit countering foreign disinformation
-
Germany sees 'worrying' record dry spell in early 2025
-
Israel says 30 percent of Gaza turned into buffer zone
-
TikTok tests letting users add informative 'Footnotes'
-
Global uncertainty will 'certainly' hit growth: World Bank president
-
EU lists seven 'safe' countries of origin, tightening asylum rules
-
Chelsea fans must 'trust' the process despite blip, says Maresca
-
Rebel rival government in Sudan 'not the answer': UK
-
Prague zoo breeds near-extinct Brazilian mergansers
-
Macron to meet Rubio, Witkoff amid transatlantic tensions
-
WTO chief says 'very concerned' as tariffs cut into global trade
-
Sports bodies have 'no excuses' on trans rules after court ruling: campaigners
-
Zverev joins Shelton in Munich ATP quarters
-
The Trump adviser who wants to rewrite the global financial system
-
US senator travels to El Salvador over wrongly deported migrant
-
UN watchdog chief says Iran 'not far' from nuclear bomb
-
Trump says 'joke' Harvard should be stripped of funds
-
Macron vows punishment for French prison attackers
-
Canada central bank holds interest rate steady amid tariffs chaos
-
Rubio headed to Paris for Ukraine war talks
-
Australian PM vows not to bow to Trump on national interest
-
New attacks target France prison guard cars, home
-
Global trade uncertainty could have 'severe negative consequences': WTO chief
-
Google facing £5 bn UK lawsuit over ad searches: firms
-
Onana to return in goal for Man Utd against Lyon: Amorim
-
Tiktok bans user behind Gisele Pelicot 'starter kit' meme
-
'Put it on': Dutch drive for bike helmets
-
China's Xi meets Malaysian leaders, vows to 'safeguard' Asia allies
-
France urges release of jailed Russian journalists who covered Navalny
-
Gabon striker Boupendza dies after 11th floor fall
-
UK top court rules definition of 'woman' based on sex at birth
-
PSG keep Champions League bid alive, despite old ghosts reappearing
-
Stocks retreat as US hits Nvidia chip export to China
-
China's Xi meets Malaysian leaders in diplomatic charm offensive
-
Israel says no humanitarian aid will enter Gaza
-
Anxiety clouds Easter for West Bank Christians
-
Pocket watch found on Titanic victim to go on sale in UK
-
UK top court rules definition of 'a woman' based on sex at birth
-
All Black Ioane to join Leinster on six-month 'sabbatical'
-
Barca suffer morale blow in Dortmund amid quadruple hunt
-
China tells Trump to 'stop threatening and blackmailing'
-
Iran FM says uranium enrichment 'non-negotiable' after Trump envoy urged halt
-
Automakers hold their breath on Trump's erratic US tariffs
-
Cycling fan admits throwing bottle at Van der Poel was 'stupid'
-
Troubled Red Bull search for path back to fast lane
-
China's forecast-beating growth belies storm clouds ahead: analysts
NYSE - LSE
Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its audited financial statements for the fiscal year ended December 31, 2024. The audit was conducted by Aloba Awomolo & Partners LLP, Chartered Professional Accountants, who were engaged earlier this year as Bionoid's external auditor.
"This marks an important milestone for Bionoid," said Wayne Cockburn, CEO of Bionoid Pharma. "Completing our 2024 audit puts us in a strong position as we now shift our focus toward the next phase of our corporate growth strategy - including the work required to advance our application to uplist to a more senior stock exchange. We remain committed to transparency, strong governance, and delivering long-term value to our shareholders."
The audited financial statements will be filed on https://www.otcmarkets.com/.
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: | |
OTC Markets: | BINP |
X (formerly Twitter): | @BionoidPharminc |
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
D.Moore--AMWN
